These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25830098)

  • 21. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients.
    Abe N; Kato S; Tsuchida T; Sugimoto K; Saito R; Verschuren L; Kleemann R; Oka K
    Biol Open; 2019 May; 8(5):. PubMed ID: 31023717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease.
    Griffett K; Burris TP
    Biochem Biophys Res Commun; 2016 Oct; 479(3):424-428. PubMed ID: 27680310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice.
    Legry V; Van Rooyen DM; Lambert B; Sempoux C; Poekes L; Español-Suñer R; Molendi-Coste O; Horsmans Y; Farrell GC; Leclercq IA
    Clin Sci (Lond); 2014 Oct; 127(7):507-18. PubMed ID: 24766485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
    Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
    Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.
    Farrell GC; Mridha AR; Yeh MM; Arsov T; Van Rooyen DM; Brooling J; Nguyen T; Heydet D; Delghingaro-Augusto V; Nolan CJ; Shackel NA; McLennan SV; Teoh NC; Larter CZ
    Liver Int; 2014 Aug; 34(7):1084-93. PubMed ID: 24107103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
    Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
    Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.
    Verbeek J; Lannoo M; Pirinen E; Ryu D; Spincemaille P; Vander Elst I; Windmolders P; Thevissen K; Cammue BP; van Pelt J; Fransis S; Van Eyken P; Ceuterick-De Groote C; Van Veldhoven PP; Bedossa P; Nevens F; Auwerx J; Cassiman D
    Gut; 2015 Apr; 64(4):673-83. PubMed ID: 24917551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
    Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
    Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
    Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
    J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.
    Wouters K; van Bilsen M; van Gorp PJ; Bieghs V; Lütjohann D; Kerksiek A; Staels B; Hofker MH; Shiri-Sverdlov R
    FEBS Lett; 2010 Mar; 584(5):1001-5. PubMed ID: 20114046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis.
    Magee N; Ahamed F; Eppler N; Jones E; Ghosh P; He L; Zhang Y
    Liver Res; 2022 Dec; 6(4):238-250. PubMed ID: 36864891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
    Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
    World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice.
    Kishina M; Koda M; Kato J; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y
    Hepatol Res; 2014 Aug; 44(8):888-896. PubMed ID: 23777387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.